If you are a doctor, researcher or a licensed practitioner that uses or studies bacteriophages and would like to share your work, contact us.
Fedor Zurabov, from MicroMir, presents a new review proposing Phagobiotics as a framework for defined, quality-controlled bacteriophages designed for selective, non-therapeutic modulation of the gut microbiota.
MicroMir shares the first comparative clinical evaluation of inhaled phages for multidrug-resistant Klebsiella pneumoniae as an adjunct to antibiotics for ventilator-associated Pneumonia.
Dr. Gladkov and his team share insights into the skin microbiota, skin-gut axis, and the role of phages in acne treatment with bacteriophages.
MicroMir shares insights on using Phage Mimir124 against multidrug-resistant Uropathogenic Escherichia coli in a patient with neurogenic bladder dysfunction.
Magdalena Pełka and Monika Adamczyk-Popławska share a pioneering advancement in phage therapy for Gonorrhea by harnessing Neisseria gonorrhoeae prophages to fight multi-drug resistant bacteria, opening up new possibilities for personalized …
Alena Kaltenbrunner shares an exciting development focused on targeting tumors, using phage design, leveraging bacteriophage biology in precision therapy.
Dr. Gladkov and his team share insights on using bacteriophage therapy in infants who suffer from atopic dermatitis, by focusing on modulating the gut microbiota.
M.Sc. Estêvão Brasiliense de Souza shares an overview on the research focused on the potential of bacteriophages as clinical immune modulators.
Researchers study the role of phages in the human gut microbiota, focusing on gut health and exploring phage-host relationships in the complex microbial environment.
Dr. Swapnil Ganesh Sanmukh shares an overview on the research focused on the potential of bacteriophages as anticancer agents.
One Ecosystem | Three Platforms
